117 related articles for article (PubMed ID: 16938579)
21. [Influence of abnormalities of TP53 and ATM genes for course of B-cell chronic lymphocytic leukemia].
Rupniewska ZM; Wasik-Szczepanek E
Postepy Hig Med Dosw; 2001; 55(6):815-28. PubMed ID: 11875779
[TBL] [Abstract][Full Text] [Related]
22. Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia.
Ouillette P; Li J; Shaknovich R; Li Y; Melnick A; Shedden K; Malek SN
Genes Chromosomes Cancer; 2012 Dec; 51(12):1125-32. PubMed ID: 22952040
[TBL] [Abstract][Full Text] [Related]
23. ATM mutations and protein expression are not associated with familial B-CLL cases.
Ishibe N; Goldin LR; Caporaso NE; Sgambati MT; Dean M; Albitar M; Manshouri T; Gerrard B; Marti GE
Leuk Res; 2003 Oct; 27(10):973-5. PubMed ID: 12860021
[No Abstract] [Full Text] [Related]
24. The value of fluorescence in situ hybridization for the detection of 11q in multiple myeloma.
González MB; Hernández JM; García JL; Lumbreras E; Castellanos M; Hernández JM; Fernández-Calvo J; Gutiérrez NC; San Miguel JF
Haematologica; 2004 Oct; 89(10):1213-8. PubMed ID: 15477206
[TBL] [Abstract][Full Text] [Related]
25. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
[TBL] [Abstract][Full Text] [Related]
26. Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage.
Britt-Compton B; Lin TT; Ahmed G; Weston V; Jones RE; Fegan C; Oscier DG; Stankovic T; Pepper C; Baird DM
Leukemia; 2012 Apr; 26(4):826-30. PubMed ID: 21986843
[No Abstract] [Full Text] [Related]
27. Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment.
Trbusek M; Malcikova J; Smardova J; Kuhrova V; Mentzlova D; Francova H; Bukovska S; Svitakova M; Kuglik P; Linkova V; Doubek M; Brychtova Y; Zacal J; Kujickova J; Pospisilova S; Dvorakova D; Vorlicek J; Mayer J
Leukemia; 2006 Jun; 20(6):1159-61. PubMed ID: 16572201
[No Abstract] [Full Text] [Related]
28. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.
Alvi AJ; Austen B; Weston VJ; Fegan C; MacCallum D; Gianella-Borradori A; Lane DP; Hubank M; Powell JE; Wei W; Taylor AM; Moss PA; Stankovic T
Blood; 2005 Jun; 105(11):4484-91. PubMed ID: 15692065
[TBL] [Abstract][Full Text] [Related]
29. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.
Pettitt AR; Sherrington PD; Stewart G; Cawley JC; Taylor AM; Stankovic T
Blood; 2001 Aug; 98(3):814-22. PubMed ID: 11468183
[TBL] [Abstract][Full Text] [Related]
30. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.
Austen B; Skowronska A; Baker C; Powell JE; Gardiner A; Oscier D; Majid A; Dyer M; Siebert R; Taylor AM; Moss PA; Stankovic T
J Clin Oncol; 2007 Dec; 25(34):5448-57. PubMed ID: 17968022
[TBL] [Abstract][Full Text] [Related]
31. Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia.
Rudd MF; Sellick GS; Webb EL; Catovsky D; Houlston RS
Blood; 2006 Jul; 108(2):638-44. PubMed ID: 16574953
[TBL] [Abstract][Full Text] [Related]
32. A putative "hepitype" in the ATM gene associated with chronic lymphocytic leukemia risk.
Martín-Guerrero I; Enjuanes A; Richter J; Ammerpohl O; Colomer D; Ardanaz M; Marco F; Salas A; Campo E; Siebert R; García-Orad A
Genes Chromosomes Cancer; 2011 Nov; 50(11):887-95. PubMed ID: 21910157
[TBL] [Abstract][Full Text] [Related]
33. Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia.
Herholz H; Kern W; Schnittger S; Haferlach T; Dicker F; Haferlach C
Cancer Genet Cytogenet; 2007 Apr; 174(1):57-60. PubMed ID: 17350468
[TBL] [Abstract][Full Text] [Related]
34. A unique lethal blastoid transformation of B-cell chronic lymphocytic leukemia carrying ATM/11q deletion and trisomy 12.
Lu Y; Huang Q
Leuk Res; 2009 Aug; 33(8):e124-6. PubMed ID: 19269030
[No Abstract] [Full Text] [Related]
35. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic significance of p53 and ATM gene deletion in patients with chronic lymphocytic leukemia].
Xu W; Li JY; Li L; Wu YJ; Yu H; Shen QD; Qiu HX
Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):450-3. PubMed ID: 19035176
[TBL] [Abstract][Full Text] [Related]
37. Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features.
Woyach JA; Lozanski G; Ruppert AS; Lozanski A; Blum KA; Jones JA; Flynn JM; Johnson AJ; Grever MR; Heerema NA; Byrd JC
Leukemia; 2012 Jun; 26(6):1442-4. PubMed ID: 22289993
[No Abstract] [Full Text] [Related]
38. ATM mutations in sporadic lymphoid tumours.
Stankovic T; Stewart GS; Byrd P; Fegan C; Moss PA; Taylor AM
Leuk Lymphoma; 2002 Aug; 43(8):1563-71. PubMed ID: 12400598
[TBL] [Abstract][Full Text] [Related]
39. Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies.
Gaudio E; Spizzo R; Paduano F; Luo Z; Efanov A; Palamarchuk A; Leber AS; Kaou M; Zanesi N; Bottoni A; Costinean S; Rassenti LZ; Nakamura T; Kipps TJ; Aqeilan RI; Pekarsky Y; Trapasso F; Croce CM
Blood; 2012 Jan; 119(1):180-7. PubMed ID: 22065599
[TBL] [Abstract][Full Text] [Related]
40. Missense mutations at ATM gene and cancer risk.
Vorechovsky I; Luo L; Ortmann E; Steinmann D; Dörk T
Lancet; 1999 Apr; 353(9160):1276. PubMed ID: 10217116
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
